特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
914583

希少疾患治療薬の世界市場 (2019-2029年):希少癌・希少代謝性疾患・希少神経疾患・希少血液疾患・希少感染症

Global Rare Disease Drugs Market Forecast 2019-2029: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 250 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=143.57円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

希少疾患治療薬の世界市場 (2019-2029年):希少癌・希少代謝性疾患・希少神経疾患・希少血液疾患・希少感染症
出版日: 2019年08月01日
発行: Visiongain Ltd
ページ情報: 英文 250 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

2024年における世界の希少疾患治療薬の市場は2570億ドルと予測されており、予測期間中は11.3%のCAGR (年間複合成長率) で成長すると予測されています。

当レポートでは、世界の希少疾患治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、薬剤・用途・流通経路・地域/主要国別の動向と市場規模の推移と予測、薬剤開発パイプラインの動向、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 イントロダクション:希少疾患

  • 希少疾患とは
  • 希少疾患の特徴
  • 希少疾患関連データ・統計
  • 課題
  • 希少疾患のタイプ

第3章 希少疾患治療薬市場の分析・予測

  • 市場概要
  • 世界の希少疾患治療薬市場
  • 世界の希少疾患治療薬市場:売上予測
  • 市場シェアの変化の見通し:地域別

第4章 希少疾患:定性分析

  • 成長推進因子
  • 成長抑制因子
  • 市場機会

第5章 希少疾患治療薬市場の分析・予測:薬剤別

  • 市場概要
  • 市場予測
    • Revlimid
    • MabThera/Rituxan
    • Opdivo
    • Imbruvica
    • Sprycel
    • Avonex
    • Tasigna
    • Copaxone
    • Rebif
    • Gleevec
    • Velcade
    • その他

第6章 希少疾患治療薬市場の分析・予測:用途別

  • 市場概要
  • 市場予測
    • 希少癌
    • 希少代謝性疾患
    • 希少神経疾患
    • 希少血液疾患
    • 希少感染症
    • その他

第7章 希少疾患治療薬市場の分析・予測:流通経路別

  • 市場概要
  • 市場予測
    • 専門薬局
    • 院内薬局
    • 小売薬局

第8章 パイプライン分析

  • 革新的希少疾患治療薬のパイプライン
    • 希少癌
    • 希少自己免疫疾患
    • 血液関連希少疾患
    • 希少遺伝性疾患
    • 希少感染症

第9章 主要国市場の分析・予測

  • 地域別内訳
  • 地域市場予測
  • 市場シェアの変化の見通し
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
  • その他の地域
    • ブラジル
    • メキシコ
    • ロシア
    • 南アフリカ

第10章 主要企業

  • Hoffmann-La Roche Ltd.
  • AbbVie
  • Pfizer
  • 武田薬品工業
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Teva Pharmaceuticals
  • Sanofi S.A.

第11章 定性分析

  • SWOT分析
  • ポーターのファイブフォース分析

第12章 総論

図表

List of Table

  • Table 2.1 List of Major Rare Oncology Diseases
  • Table 2.2 List of Metabolic Diseases
  • Table 2.3 List of Neurologic Diseases
  • Table 2.4 List of Hematology Diseases
  • Table 2.5 List of Some of the Major Other Rare Diseases
  • Table 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 5.1 Global Rare Disease Drugs Market Forecast by Drugs: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 5.2 Global Revlimid Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.3 Global MabThera/Rituxan Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.4 Global Opdivo Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.5 Global Imbruvica Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.6 Global Sprycel Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.7 Global Avonex Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.8 Global Tasigna Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.9 Global Copaxone Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.10 Global Rebif Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.11 Global Gleevec Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.12 Global Velcade Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.13 Global Other Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.1 Global Rare Disease Drugs Market Forecast by Application: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 6.2 Global Rare Oncology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.3 Global Rare Metabolic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.4 Global Rare Neurologic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.5 Global Hematology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.6 Global Infectious Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.7 Other Rare Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.1 Global Rare Disease Drugs Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 7.2 Global Specialty Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.3 Global Hospital Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.4 Global Retail Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 8.1 Rare Oncology Drugs in Development, 2018
  • Table 8.2 Rare Autoimmune Disease Drugs in Development, 2018
  • Table 8.3 Blood-related Rare Disease Drugs in Development, 2018
  • Table 8.4 Rare Genetic Disease Drugs in Development, 2018
  • Table 8.5 Rare Infectious Disease Drugs in Development, 2018
  • Table 9.1 World Rare Disease Drugs Market by Region: Revenue ($bn) and Market Share (%) 2018 and 2029
  • Table 9.2 Global Rare Disease Drugs Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.3 North America Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.4 North America Rare Disease Drugs Market by Region Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.5 US Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.6 Canada Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.7 Europe Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.8 Europe Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.9 Germany Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.10 UK Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.11 French Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.12 Italian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.13 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.14 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.15 Asia-Pacific Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.16 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.17 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.18 Indian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.19 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.20 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.21 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.22 Russia Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.23 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 10.1 Overview: Hoffmann-La Roche Ltd.
  • Table 10.2 Overview: AbbVie
  • Table 10.3 Overview: Pfizer
  • Table 10.4 Overview: Takeda Pharmaceuticals
  • Table 10.5 Overview: Bristol-Myers Squibb Company
  • Table 10.6 Overview: Merck & Co., Inc
  • Table 10.7 Overview: Novartis
  • Table 10.8 Overview: Celgene Corporation
  • Table 10.9 Overview: Teva Pharmaceuticals
  • Table 10.10 Overview: Sanofi S.A.

List of Figure

  • Figure 1.1 Global Rare Disease Drugs Market Segmentation Overview, 2018
  • Figure 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029
  • Figure 3.2 Global Rare Disease Drugs Market Forecast Share (%) by Region 2019-2029
  • Figure 4.1 Rare Disease Drugs Market: Drivers 2019-2029
  • Figure 4.2 Rare Disease Drugs Market: Restraints 2019-2029
  • Figure 4.3 Rare Disease Drugs Market: Trends 2019-2029
  • Figure 5.1 Global Rare Disease Drugs by Drugs Market Share Forecast (%) 2019-2029
  • Figure 5.2 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2018
  • Figure 5.3 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2019
  • Figure 5.4 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2024
  • Figure 5.5 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2029
  • Figure 5.6 Global Revlimid Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.7 Global MabThera/Rituxan Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.8 Global Opdivo Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.9 Global Imbruvica Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.10 Global Sprycel Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.11 Global Avonex Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.12 Global Tasigna Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.13 Global Copaxone Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.14 Global Rebif Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.15 Global Gleevec Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.16 Global Velcade Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.17 Global Other Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.1 Global Rare Disease Drugs Market Forecast by Application Market Share (%) 2019-2029
  • Figure 6.2 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2018
  • Figure 6.3 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2024
  • Figure 6.4 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2029
  • Figure 6.5 Global Rare Oncology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.6 Global Rare Metabolic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.7 Global Rare Neurologic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.8 Global Hematology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.9 Global Infectious Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.10 Other Rare Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.1 Global Rare Disease Drugs by Distribution Channel Market Share (%) 2019-2029
  • Figure 7.2 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2018
  • Figure 7.3 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2024
  • Figure 7.4 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2029
  • Figure 7.5 Global Specialty Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.6 Global Hospital Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.7 Global Retail Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.1 Global Rare Disease Drugs Market by Region: Revenues (%), 2018
  • Figure 9.2 Global Rare Disease Drugs Market by Region: Revenues (%), 2024
  • Figure 9.3 Global Rare Disease Drugs Market by Region: Revenues (%), 2029
  • Figure 9.4 North America Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.5 North America Rare Disease Drugs Market by Region Forecast: Market Share 2019-2029
  • Figure 9.6 US Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.7 Canada Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.8 Europe Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.9 Europe Rare Disease Drugs Market by Country: Revenue (%), 2019-2029
  • Figure 9.10 Germany Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.11 UK Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.12 French Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.13 Italian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.14 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.15 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.16 Asia-Pacific Rare Disease Drugs Market by Country: Revenue (%), 2019-2029
  • Figure 9.17 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.18 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.19 Indian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.20 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.21 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.22 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.23 Russia Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.24 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 10.1 Hoffmann-La Roche Ltd.: Financial Overview, 2016-2018
  • Figure 10.2 AbbVie: Financial Overview, 2016-2018
  • Figure 10.3 Pfizer: Financial Overview: 2016-2018
  • Figure 10.4 Takeda Pharmaceuticals: Financial Overview 2016-2018
  • Figure 10.5 Bristol-Myers Squibb Company: Financial Overview 2016- 2018
  • Figure 10.6 Merck & Co., Inc: Financial Overview 2016-2018
  • Figure 10.7 Novartis: Financial Overview 2016-2018
  • Figure 10.8 Celgene Corporation: Financial Overview 2016-2018
  • Figure 10.9 Teva Pharmaceuticals: Financial Overview 2016-2018
  • Figure 10.10 Sanofi S.A.: Financial Overview 2016-2018
  • Figure 11.1 SWOT Analysis of the Global Rare Disease Drugs Market, 2019-2029
  • Figure 12.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029
  • Figure 12.2 Global Rare Disease Drugs Market Forecast Share (%, By Region 2018, 2024 & 2029)

List of Companies Mentioned in the Report:

  • AB Science
  • AbbVie
  • Acceleron Pharma & Celgene
  • Acer Therapeutics
  • Actavis Generics
  • Actelion Pharmaceuticals
  • Actinium Pharmaceuticals
  • Adaptimmune
  • Aduro BioTech
  • Advanced Accelerator Applications
  • Advantagene
  • Advaxis
  • Advenchen Laboratories
  • Affimed Therapeutics & Merck
  • Agenus
  • Agios Pharmaceuticals
  • Akashi Therapeutics
  • Akcea Therapeutics
  • Alcobra
  • Alexion Pharmaceuticals
  • Alkeus Pharmaceuticals
  • Allergan
  • Alnylam Pharmaceuticals
  • Ambit Biosciences
  • AmerisourceBergen Corporation
  • Amgen
  • Amicus Therapeutics
  • Andarix Pharmaceuticals
  • Angimmune
  • Angiochem
  • AntiVirus Therapeutics
  • Applied Genetic Technologies
  • Araim Pharmaceuticals
  • Arch Biopartners
  • arGentis Pharmaceuticals
  • ARIAD Pharmaceuticals
  • ArmaGen Technologies
  • ARMGO Pharma
  • AROG Pharmaceuticals
  • ArQule
  • ArQule
  • Array BioPharma
  • Arrowhead Research
  • Astellas Pharma US
  • Astex Pharmaceuticals
  • AstraZeneca
  • ATARA Biotherapeutics
  • Atox Bio
  • aTyr Pharma
  • Baxalta
  • Bayer HealthCare Pharmaceuticals
  • Belrose Pharmaceuticals
  • BerGenBio
  • BioBlast Pharma
  • BioCryst Pharmaceuticals
  • Biodel
  • Biogen
  • BioInvent International
  • BioLineRx
  • BioMarin Pharmaceutical
  • BioNTech
  • Bio-Path Holdings
  • Biotest Pharmaceuticals
  • Blaze Bioscience
  • bluebird bio
  • Blueprint Medicines
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol-Myers Squibb
  • Burzynski Research Institute
  • Caladrius Biosciences
  • Cancer Advances
  • Cancer Prevention Pharmaceutical
  • Capricor Therapeutics
  • Cardinal Health, Inc.
  • CASI Pharmaceuticals
  • Catabasis Pharmaceuticals
  • Cavion
  • Celator Pharmaceuticals
  • Celgene Corporation
  • Cell Medica
  • Cell Therapeutics
  • Cellectar Biosciences
  • CEL-SCI
  • Celsion
  • Celtaxsys
  • Cempra Pharmaceuticals
  • CerRx
  • Cerulean Pharma
  • ChemoCentryx
  • Chugai Pharma
  • Cidara Therapeutics
  • Cleave Biosciences
  • Clementia Pharmaceuticals
  • Clinuvel
  • Clovis Oncology
  • Confluence Pharmaceuticals
  • Corbus Pharmaceuticals
  • Cornerstone Pharmaceuticals
  • Cortice Biosciences
  • Critical Outcome Technologies
  • Curis
  • Cyclacel
  • CymaBay Therapeutics
  • CytRx
  • Daiichi Sankyo
  • Deciphera Pharmaceuticals
  • Delcath Systems
  • DelMar Pharmaceuticals
  • Diffusion Pharmaceuticals
  • Dimension Therapeutics
  • Diurnal
  • DNAtrix
  • Eddingpharm
  • Edimer Pharmaceuticals
  • Edison Pharmaceuticals
  • Eiger Biopharmaceuticals
  • Eisai
  • Eleison Pharmaceuticals
  • Eli Lilly
  • EMD Serono & Pfizer
  • Emergent BioSolutions
  • Emmaus Medical
  • Epitopoietic Research
  • Epizyme
  • Epizyme
  • EryDel
  • Escala Therapeutics
  • Essentialis
  • Five Prime Therapeutics
  • Fortress Biotech
  • Gamida Cell
  • Gem Pharmaceuticals
  • Gen Sight Biologics
  • Genentech
  • GenSpera
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Gliknik
  • Global Blood Therapeutics
  • GlycoMimetics
  • Golden Biotechnology
  • Gradalis
  • Grifols Therapeutics
  • GW Pharma
  • Halozyme Therapeutics
  • Hanmi
  • Hoffmann-La Roche Ltd
  • Horizon Pharma
  • Idera Pharmaceuticals
  • Ignyta
  • Immatics Biotechnologies
  • Immune Design
  • Immune Pharmaceuticals
  • Immune Response BioPharma
  • Immune Therapeutics
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Immunomedics
  • Immunovaccine Technologies
  • Incyte
  • Infinity Pharmaceuticals
  • InnoPharma
  • Insmed
  • Insys Therapeutics
  • Ionis Pharmaceuticals
  • Ionis Pharmaceuticals
  • Ipsen Biopharmaceuticals
  • IRX Therapeutics
  • Janssen Biotech
  • jCyte
  • Juno Therapeutics
  • Karyopharm Therapeutics
  • Kevelt
  • Kyowa Kirin USA
  • LeafBio
  • Lexicon Pharmaceuticals
  • Lion Biotechnologies
  • LipimetiX Development
  • MabVax Therapeutics
  • Marathon Pharmaceuticals
  • Marina Biotech
  • Mast Therapeutics
  • McKesson Corporation
  • MedImmune
  • MEI Pharma
  • Merck & Co., Inc
  • Millendo Therapeutics
  • Millennium Pharmaceuticals
  • Milo Biotechnology
  • Minneamrita Therapeutics
  • Mirati Therapeutics
  • Momenta Pharmaceuticals
  • MorphoSys
  • Nektar Therapeutics
  • NeOnc Technologies
  • Neuren Pharmaceuticals
  • Neurolixis
  • Neurotech USA
  • NGM Biopharmaceuticals
  • NightstaRx
  • Nivalis Therapeutics
  • NKT Therapeutics
  • Novartis Pharmaceuticals
  • Novo Nordisk
  • Novoteris
  • Ocata Therapeutics
  • Omeros
  • On Target Laboratories
  • Oncolix
  • Oncolytics Biotech
  • OncoMed Pharmaceuticals
  • OncoMed Pharmaceuticals & GlaxoSmithKline
  • Onconova Therapeutics
  • OncoPep
  • Oncopeptides
  • OPKO Biologics
  • OSE Pharma
  • Otsuka Pharmaceutical
  • OXiGENE
  • Patagonia Pharmaceuticals
  • Peregrine Pharmaceuticals
  • Pfizer Inc.
  • Pharmacyclics
  • PharmaCyte Biotech
  • PharmaEssentia, Corporation
  • PharmaMar USA
  • Plexxikon
  • PNP Therapeutics
  • Polaris Pharmaceuticals
  • Polynoma
  • Prana Biotechnology
  • Precision Biologics
  • Progenics Pharmaceuticals
  • Prolong Pharmaceuticals
  • Promedior
  • ProMetic Biotherapeutics
  • ProNAi Therapeutics
  • ProQR Therapeutics
  • Protalex
  • Provectus Pharmaceuticals
  • PTC Therapeutics
  • QLT
  • Quest PharmaTech
  • Qurient
  • Raptor Pharmaceutical
  • Rebiotx
  • Regeneron Pharmaceuticals
  • Regulus Therapeutics & Sanofi US
  • Retrophin
  • RetroSense Therapeutics
  • ReveraGen Biopharma
  • Rexahn Pharmaceuticals
  • Rhythm Metabolics
  • Rigel Pharmaceuticals
  • River Vision
  • Roche
  • Sanofi S. A.
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics
  • Savara Pharmaceuticals
  • Seattle Genetics
  • Selexys Pharmaceuticals
  • SELLAS Life Sciences
  • Sequella
  • Seres Health
  • Shire plc
  • SIGA Technologies
  • Sigma-Tau Pharmaceuticals
  • SillaJen Biotherapeutics
  • Soligenix
  • Soricimed Biopharma
  • Spark Therapeutics
  • StemcentRx
  • Stemline Therapeutics
  • Sun BioPharma
  • Sun Pharmaceuticals
  • Sunesis Pharmaceuticals
  • Takeda Pharmaceuticals
  • Tapimmune
  • Tarix Orphan
  • TESARO
  • TetraLogic Pharmaceuticals
  • Teva Pharmaceutical
  • TG Therapeutics
  • Tiziana Life Sciences
  • Tocagen
  • Tolero Pharmaceuticals
  • Tracon Pharmaceuticals
  • TransDerm
  • Triphase Research & Development
  • Triphase Research and Development
  • Ultragenyx Pharmaceutical
  • Ultragenyx Pharmaceutical
  • uniQure
  • UroGen
  • Vascular Biogenics
  • VentiRx Pharmaceuticals
  • Verastem
  • Vertex Pharmaceuticals
  • Viamet Pharmaceuticals
  • Vicus Therapeutics
  • Viralytics
  • Viventia Biotech
  • VivoLux
  • Vtesse
  • Wilson Therapeutics
  • Xeris Pharmaceuticals
  • XOMA
  • Ziopharm Oncology
  • Zogenix
  • Zywie
目次
Product Code: PHA0461

The global rare disease drugs market is estimated to reach $257bn in 2024 and is expected to grow at a CAGR of 11.3% throughout the forecast period. In 2018, rare oncology diseases segment held 36% of share in the global rare disease drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 145 charts - all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global rare disease drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Rare Disease Drugs Market forecasts from 2019-2029

Revenue forecasts for the global rare disease drugs market by application from 2019-2029:

  • Rare Oncology Diseases
  • Rare Metabolic Diseases
  • Rare Neurologic Diseases
  • Rare Hematology Diseases
  • Rare Infectious Diseases
  • Other Rare Diseases

Revenue forecasts for the global rare disease drugs market by distribution channel from 2019-2029:

  • Specialty Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Revenue forecasts for the global rare disease drugs market by drug from 2019-2029:

  • Avonex
  • Copaxone
  • Gleevec
  • Imbruvica
  • MabThera/Rituxan
  • Opdivo
  • Rebif
  • Revlimid
  • Sprycel
  • Tasigna
  • Velcade
  • Other Drugs

Revenue forecasts for the rare disease drugs market by Regional and National Market from 2019-2029:

  • North America (US, Canada)
  • Europe (Germany, UK, France, Italy, Spain)
  • Asia-Pacific (Japan, China, India, South Korea)
  • RoW (Brazil, Mexico, South Africa, Russia)

Profiles and discussion on the leading companies in the rare disease drugs market:

  • AbbVie
  • Bristol-Myers Squibb (BMS)
  • Celgene
  • Merck & Co., Inc.
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • Teva

Rare disease drugs pipeline analysis covering rare oncology drugs, rare autoimmune disease drugs, blood-related rare disease drugs, rare genetic disease drugs and rare infectious disease drugs.

SWOT Analysis and Porter's Five Forces analysis of the global rare disease drugs market

Discussion on factors that drive and restrain the global rare disease drugs market as well as opportunities in this market.

Key Questions Answered by this Report:

  • What are the global revenue prospects for the period 2019 to 2029?
  • What are the leading national market potentials from 2019 to 2029?
  • How is the rare disease drugs market evolving?
  • What is driving and restraining the rare disease drugs market?
  • What are the market shares of each segment of the overall rare disease drugs market?
  • How will main rare disease drugs submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each rare disease drugs submarket develop from 2018 to 2029?
  • Which therapies can succeed and what revenues could they generate to 2029?
  • What will be the main commercial drivers for the market from 2018 to 2029?
  • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Rare Disease Drugs Market. You find data, trends and predictions.

Buy our report today Global Rare Disease Drugs Market Forecast 2019-2029: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Rare Disease Drugs Market Overview
  • 1.2 Global Rare Disease Drugs Market Segmentation
  • 1.3 Overview of Findings
  • 1.4 Structure of the Report
  • 1.5 Why You Should Read This Report
  • 1.6 Key Questions Answered by This Analytical Report
  • 1.7 Who is This Report For?
  • 1.8 Methods of the Study
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Introduction to Rare Diseases

  • 2.1 What Are Rare Diseases?
  • 2.2 Characteristics of Rare Diseases
  • 2.3 Rare Disease Facts and Statistics
  • 2.4 Enduring Challenges of Rare Diseases
  • 2.5 Types of Rare Diseases
    • 2.5.1 Rare Oncology Diseases
    • 2.5.2 Rare Metabolic Diseases
    • 2.5.3 Rare Neurologic Diseases
    • 2.5.4 Rare Hematology Diseases
    • 2.5.5 Rare Infectious Diseases
    • 2.5.6 Other Rare Diseases

3. Rare Diseases: World Market 2019-2029

  • 3.1 Rare Disease Drugs Market Overview, 2018
  • 3.2 The World Rare Disease Drugs Market
  • 3.3 World Rare Disease Drugs Market: Sales Forecast 2019-2029
  • 3.4 Changing Market Shares by Region 2019-2029

4. Rare Diseases: Qualitative Analysis 2019-2029

  • 4.1 Rare Disease Drugs Market: Drivers 2019-2029
    • 4.1.1 Increase in Prevalence of Rare Diseases
    • 4.1.2 High Investment in Rare Disease Drugs R&D
    • 4.1.3 Increase in Number of Product Approvals
    • 4.1.4 Growing Support of Government for Rare Diseases
  • 4.2 Rare Disease Drugs Market Restraints: 2019-2029
    • 4.2.1 Challenges in Treatment
    • 4.2.2 Challenges in Research and Development
    • 4.2.3 Stringent Government Regulations
  • 4.3 Rare Disease Drugs Market Opportunities: 2019-2029
    • 4.3.1 Progress in Diagnostics and Therapeutics
    • 4.3.2 Orphan Drug Opportunities
    • 4.3.3 IRDiRC Guidelines and Policies

5. Rare Disease Drugs Market by Drugs, 2019-2029

  • 5.1 Market Overview
  • 5.2 Market Forecast 2019-2029
    • 5.2.1 Revlimid: Market Forecast, 2019-2029
    • 5.2.2 MabThera/Rituxan: Market Forecast, 2019-2029
    • 5.2.3 Opdivo: Market Forecast, 2019-2029
    • 5.2.4 Imbruvica: Market Forecast, 2019-2029
    • 5.2.5 Sprycel: Market Forecast, 2019-2029
    • 5.2.6 Avonex: Market Forecast, 2019-2029
    • 5.2.7 Tasigna: Market Forecast, 2019-2029
    • 5.2.8 Copaxone: Market Forecast, 2019-2029
    • 5.2.9 Rebif: Market Forecast, 2019-2029
    • 5.2.10 Gleevec: Market Forecast, 2019-2029
    • 5.2.11 Velcade: Market Forecast, 2019-2029
    • 5.2.12 Other Drugs: Market Forecast, 2019-2029

6. Rare Disease Drugs Market by Applications, 2019-2029

  • 6.1 Market Overview
  • 6.2 Market Forecast 2019-2029
  • 6.3 Rare Oncology Diseases Market
  • 6.4 Rare Metabolic Diseases Market
  • 6.5 Rare Neurologic Diseases Market
  • 6.6 Rare Hematology Diseases Market
  • 6.7 Rare Infectious Diseases Market
  • 6.8 Other Rare Diseases Market

7. Rare Disease Drugs Market by Distribution Channel 2019-2029

  • 7.1 Market Overview
  • 7.2 Market Forecast 2019-2029
  • 7.3 Specialty Pharmacies
  • 7.4 Hospital Pharmacies
  • 7.5 Retail Pharmacies

8. Rare Disease Drugs Market - Pipeline Analysis 2019-2029

  • 8.1 Innovative Rare Disease Drugs Pipeline
    • 8.1.1 Rare Oncology Drugs in Development
    • 8.1.2 Rare Autoimmune Disease Drugs in Development
    • 8.1.3 Blood-related Rare Disease Drugs in Development
    • 8.1.4 Rare Genetic Disease Drugs in Development
    • 8.1.5 Rare Infectious Disease Drugs in Development

9. Leading National Markets 2019-2029

  • 9.1 Geographical Breakdown of the World Rare Disease Drugs Market
  • 9.2 Global Rare Disease Drugs Market: Regional Forecast 2019-2029
  • 9.3 How Will Regional Market Shares Change to 2029?
  • 9.4 North America Rare Disease Drugs Market, 2019-2029
    • 9.4.1 US Rare Disease Drugs Market Forecast 2019-2029
    • 9.4.2 Canada Rare Disease Drugs Market Forecast 2019-2029
  • 9.5 Europe Rare Disease Drugs Market, 2019-2029
    • 9.5.1 Europe Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.2 Germany Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.3 UK Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.4 French Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.5 Italian Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.6 Spanish Rare Disease Drugs Market Forecast 2019-2029
  • 9.6 Asia-Pacific Rare Disease Drugs Market 2019-2029
    • 9.6.1 Japanese Rare Disease Drugs Market Forecast 2019-2029
    • 9.6.2 Chinese Rare Disease Drugs Market 2019-2029
    • 9.6.3 Indian Rare Disease Drugs Market 2019-2029
    • 9.6.4 South Korea Rare Disease Drugs Market Forecast 2019-2029
  • 9.7 RoW Rare Disease Drugs Market 2019-2029
    • 9.7.1 Brazilian Rare Disease Drugs Market Forecast 2019-2029
    • 9.7.2 Mexico Rare Disease Drugs Market 2019-2029
    • 9.7.3 Russia Rare Disease Drugs Market Forecast 2019-2029
    • 9.7.4 South Africa Rare Disease Drugs Market Forecast 2019-2029

10. Leading Companies in the Rare Disease Drugs Market

  • 10.1 Hoffmann-La Roche Ltd.
    • 10.1.1 Financial Overview
    • 10.1.2 Recent Developments
  • 10.2 AbbVie
    • 10.2.1 Financial Overview
    • 10.2.2 Recent Developments
  • 10.3 Pfizer
    • 10.3.1 Financial Overview
    • 10.3.2 Recent Developments
  • 10.4 Takeda Pharmaceuticals
    • 10.4.1 Financial Overview
    • 10.4.2 Recent Developments
  • 10.5 Bristol-Myers Squibb Company
    • 10.5.1 Financial Overview
    • 10.5.2 Recent Developments
  • 10.6 Merck & Co., Inc.
    • 10.6.1 Financial Overview
    • 10.6.2 Recent Developments
  • 10.7 Novartis AG
    • 10.7.1 Financial Overview
    • 10.7.2 Recent Developments
  • 10.8 Celgene Corporation
    • 10.8.1 Financial Overview
    • 10.8.2 Recent Developments
  • 10.9 Teva Pharmaceuticals
    • 10.9.1 Financial Overview
    • 10.9.2 Recent Developments
  • 10.10 Sanofi S.A.
    • 10.10.1 Financial Overview
    • 10.10.2 Recent Developments

11. Rare Disease Drugs Market, Qualitative Analysis, 2019-2029

  • 11.1 Rare Disease Drugs Market: SWOT Analysis, 2019-2029
    • 11.1.1 Strengths
      • 11.1.1.1 Promising Rare Disease Drugs R&D Pipeline
      • 11.1.1.2 Increase in Healthcare Awareness
    • 11.1.2 Increase in Number of Drug Approvals
    • 11.1.3 Weaknesses
    • 11.1.4 High Research and Development Cost
    • 11.1.5 Opportunities
    • 11.1.6 Demand from Emerging Market Continues
    • 11.1.7 Increase in Government Support
    • 11.1.8 Threats
    • 11.1.9 Uncertainty of R&D Results
    • 11.1.10 Barriers to Market Entry
  • 11.2 Rare Disease Drugs Market: Porters Five Forces Analysis, 2019-2029
    • 11.2.1 Bargaining Power of Supplier: Moderate
    • 11.2.2 Bargaining Power of Buyer: Low
    • 11.2.3 Competitive Rivalry: High
    • 11.2.4 The Threat of New Entrants: Low
    • 11.2.5 Threat of Substitutes: Low

12. Conclusion

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.